Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Nektar is a clinical-stage biopharmaceutical company focused on novel immunology therapies. Its lead asset, rezpegaldesleukin, is in Phase 2b trials for atopic dermatitis and alopecia areata. The company also has a TNFR2 program (NKTR-0165/0166) and an oncology candidate (NKTR-255). The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $10,861 | $10,460 |
| Net Loss | $(44,904) | $(50,882) |
| Loss Per Share (Basic & Diluted) | $(1.82) | $(3.62) |
| Operating Cash Flow | $(44,298) | $(49,053) |
| Cash & Investments (Total) | $731,597 | $245,752 |
| Total Assets | $763,271 | $280,406 |
| Total Liabilities | $187,055 | $190,574 |
Note: Revenue consists entirely of non-cash royalty revenue related to the sale of future royalties. The company has no product sales revenue.
Material Changes vs. Prior Period
- Liquidity Surge: Cash and investments increased from $245.8 million to $731.6 million, driven by significant equity financing activities. Net proceeds from equity offerings totaled approximately $529.5 million in Q1 2026 alone.
- Reduced Net Loss: Net loss improved by 12% ($5.98 million) compared to Q1 2025, primarily due to a decrease in General and Administrative (G&A) expenses and a lower loss from the equity method investment in Gannet BioChem.
- Expense Shifts:
- R&D Expenses: Increased 17% to $35.7 million, driven by Phase 3 preparation for rezpegaldesleukin in atopic dermatitis.
- G&A Expenses: Decreased 45% to $13.4 million, largely due to reduced legal expenses.
- Restructuring: Increased to $0.8 million from $0.2 million, related to contract termination costs.
- Non-Operating Items: Non-cash interest expense on royalty liabilities increased 60% to $7.9 million. Interest income increased 48% to $4.2 million due to higher investment balances.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Clinical Progress: The company announced positive maintenance data for the Phase 2b REZOLVE-AD trial (atopic dermatitis) and topline results for the REZOLVE-AA trial (alopecia areata). Rezpegaldesleukin has received Fast Track designation for both indications.
- Capital Position: Management estimates sufficient working capital to fund operations for at least the next 12 months following recent financings.
- Future Costs: R&D expenses are expected to increase significantly in 2026 to support the Phase 3 program for atopic dermatitis. G&A expenses are expected to decrease slightly.
Risks and Contingencies
- Litigation:
- Eli Lilly: Ongoing breach of contract lawsuit regarding the rezpegaldesleukin program. A jury trial is scheduled for September 8, 2026.
- Securities Class Action: A putative class action filed March 6, 2026, alleging misleading statements regarding the REZOLVE-AA trial. The company denies the claims.
- Indian GST: A demand for approximately $3.3 million in tax refunds plus penalties; the company believes a loss is not probable and has not accrued a liability.
- Dependency: High dependence on the success of rezpegaldesleukin and reliance on third-party manufacturers (specifically Gannet BioChem for PEG reagents).
- Regulatory: Risks associated with FDA review timelines, potential government shutdowns, and the uncertainty of clinical trial outcomes.
Investor Verification Checklist
- Financing Dilution: Verify the impact of the 19.4 million shares sold between July 2025 and April 2026 on shareholder dilution and future capital needs.
- Non-Cash Revenue: Confirm understanding that reported revenue ($10.9M) is non-cash royalty revenue from past asset sales and does not reflect operational cash generation.
- Litigation Exposure: Monitor the status of the Eli Lilly lawsuit and the new securities class action, as unfavorable outcomes could materially impact financial condition.
- Cash Burn Rate: Assess the sustainability of the $44.3 million quarterly operating cash burn against the $731.6 million cash balance, considering the anticipated increase in Phase 3 R&D costs.
- Supply Chain: Verify the stability of the supply agreement with Gannet BioChem for critical PEG reagents used in manufacturing.